Compare CRNX & CATY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRNX | CATY |
|---|---|---|
| Founded | 2008 | 1962 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.2B |
| IPO Year | 2018 | 1996 |
| Metric | CRNX | CATY |
|---|---|---|
| Price | $83.98 | $64.85 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 4 |
| Target Price | ★ $76.75 | $52.50 |
| AVG Volume (30 Days) | ★ 6.8M | 517.2K |
| Earning Date | 05-07-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 2.77% |
| EPS Growth | N/A | ★ 14.94 |
| EPS | N/A | ★ 1.29 |
| Revenue | $1,039,000.00 | ★ $53,793,000.00 |
| Revenue This Year | $720.10 | $20.37 |
| Revenue Next Year | $184.67 | $5.41 |
| P/E Ratio | ★ N/A | $49.53 |
| Revenue Growth | N/A | ★ 2.93 |
| 52 Week Low | $25.83 | $44.65 |
| 52 Week High | $84.00 | $64.29 |
| Indicator | CRNX | CATY |
|---|---|---|
| Relative Strength Index (RSI) | 90.37 | 61.58 |
| Support Level | $43.40 | $60.38 |
| Resistance Level | $84.00 | N/A |
| Average True Range (ATR) | 0.19 | 1.04 |
| MACD | -1.64 | 0.02 |
| Stochastic Oscillator | 71.70 | 87.54 |
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
Cathay General Bancorp is a regional bank predominantly serving the Chinese-American community. The company's policy is to reach out and actively offer services to low-to-moderate income groups in the delineated branch service areas. It predominantly provides services such as checking and deposit, lines of credit, commercial and commercial real estate loans, merchant services and payment processing, treasury management services, international banking and financing services, and other customary banking services to individuals, professionals, and small to medium-sized businesses. Through its Wealth Management unit, the company also offers investment products and services, such as stocks, bonds, mutual funds, insurance, annuities, and advisory services.